Wells Fargo Sticks to Their Buy Rating for BioNTech SE (BNTX)
In a report released today, Mohit Bansal from Wells Fargo maintained a Buy rating on BioNTech SE, with a price target of $150.00.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
According to TipRanks, Bansal is a 5-star analyst with an average return of 9.9% and a 57.50% success rate. Bansal covers the Healthcare sector, focusing on stocks such as Merck & Company, Pfizer, and Jazz Pharmaceuticals.
In addition to Wells Fargo, BioNTech SE also received a Buy from Canaccord Genuity’s John Newman in a report issued today. However, yesterday, TD Cowen assigned a Hold rating to BioNTech SE (NASDAQ: BNTX).
Based on BioNTech SE’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $1.52 billion and a GAAP net loss of $28.7 million. In comparison, last year the company earned a revenue of $1.24 billion and had a net profit of $198.1 million
Based on the recent corporate insider activity of 11 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BNTX in relation to earlier this year.
Read More on BNTX:
Disclaimer & DisclosureReport an Issue
- BioNTech price target lowered to $130 from $145 at Citi
- Balancing Near-Term Headwinds and Strategic Transition: Why a Hold Rating Remains Warranted
- BioNTech: Attractive Near-Cash Valuation with Robust Late-Stage Pipeline Offsetting Revenue Declines and Leadership Transition Risks
- Jefferies cuts BioNTech price target, says stock is cheap
- Clear Street lowers BioNTech price target, says buy on weakness
